FDA Approves Expandable Heart Valve Designed to Grow With Children
The U.S. Food and Drug Administration has approved a surgical artificial pulmonary valve for children that can be widened inside the body as the child grows. Engadget The announcement came Oct. 1. The device, called the Autus Size-Adjustable Valve, was developed by Edwards Lifesciences.
The valve can be implanted at 13 millimeters in toddlers and preschool-age children. Doctors can later expand the frame from inside the body using a balloon catheter, a thin tube with a small balloon at the tip, to keep up with normal body growth. It can reach up to 22 millimeters, a size similar to adult artificial valves. The valve does not need to be replaced to be made larger.
It is the first adjustable heart valve and the first to use flaps made from engineered plastic rather than animal tissue. Engadget Known in technical papers as ASAV, the device is fully synthetic. It is meant for congenital pulmonary valve disease, conditions children are born with that affect the valve. Edwards describes it as the first FDA-approved surgical pulmonary valve designed for pediatric anatomy. Edwards
The approval is the first for children to come through the FDA's Total Product Life Cycle Advisory Program, or TAP, which advises companies from early design through follow-up after approval. FDA One-year follow-up data suggests the valve may hold up better over time than other models. Engadget In pediatrics, how long an implant lasts often sets when the next procedure is needed.
The broader context here is a long-standing mismatch in children's implants. The patient grows. The device does not. In my view, what is notable about Autus is that growth is treated as part of the design, with a frame that can be opened wider in steps and flaps meant to keep working across that range.
In my view, the practical change is also worth noting. Surgeons still place the valve in an operation. Later size increases are done with a catheter, without open surgery. For families and care teams, that difference affects risk, recovery time and planning. Longer follow-up beyond one year is still needed to judge lifetime performance, and stability after expansion is the measure to watch.
In my view, TAP may prove as important as the valve itself. Children's devices often involve small patient groups, changing size needs and limited commercial return. A program that stays involved from design through postmarket data fits that problem better than a single approval checkpoint. If Autus does well over time, similar expandable implants for children should become easier to develop and update.
Looking back over longer trends, I have watched my own children outgrow shoes, clothes and bicycles in quick succession. Technology has often done its best work when it removes a limit people had learned to accept. Surgeons once had to plan for staged replacements. An adjustable, fully synthetic valve allows them to plan for growth instead.
